Low-dose ketamine infusion to facilitate opioid tapering in chronic non-cancer pain with opioid-use disorder: a historical cohort study
Authors' conclusion
A 5-day hospitalisation with a low-dose ketamine infusion appeared useful to facilitate opioid tapering in long-term opioid users with CP and OUD.
Study context
- Population
- Long-term opioid users with opioid-use disorder (OUD) and chronic non-cancer pain, outpatient progressive tapering failed, Pain Center, University Hospital of Toulouse, 2014–201917 lost to follow-up
- Participants
- 59 users
- Outcome
- Change in opioid daily dose (MME)
- Follow-up
- 1 year
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Opioid daily dose (MME)
- Baseline opioid daily dose, mg morphine milligram equivalent (MME) (±)
- 207 (±128)
- At discharge, mg MME (±), vs baseline
- 92±72 (p<0.001)
- At 3 months, mg MME (±), vs baseline
- 99±77 (p<0.001)
- At 12 months, mg MME (±)
- 103±106
- More than 50% tapering achieved immediately
- 40 patients (68%)
- Immediate cessation
- 7 patients (12%)
Observational data: associations, not effects.
Further findings
Tapering at discharge
- >50% tapering achieved immediately
- 40 (68%)
- Immediate cessation
- 7 (12%)
Safety
Tolerance and withdrawal symptoms
- Ketamine well tolerated; no significant withdrawal symptoms
Original publication
Low-dose ketamine infusion to facilitate opioid tapering in chronic non-cancer pain with opioid-use disorder: a historical cohort study. Reg Anesth Pain Med. Published 18 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →